For CVS, Q2 earnings will be a critical inflection point. A miss could trigger a breakup or further decline, making the stock ...

Pharmacy benefit manager CVS Caremark drops Zepbound coverage, estimating 10-15% savings while Eli Lilly offers self-pay ...

CVS wins a major CalPERS deal as Caremark replaces OptumRx, backed by $250M in performance guarantees and drug cost controls.

CVS Caremark will stop covering Eli Lilly’s Zepbound. Wegovy, the GLP-1 medication to treat obesity from Lilly competitor Novo Nordisk, will still be covered under plans managed by CVS Caremark.

The coverage change only applies to employer and union insurance plans ... Wegovy will enable more employers to provide coverage for the weight loss category," CVS Health Vice President of External ...

Millions of Americans could lose access to healthcare due to new Medicaid requirements in the One Big Beautiful Bill. Here ...

NEW YORK, July 14 (Reuters) - President Donald Trump's spending bill is set to raise administrative costs and make managing ...

This latest move by health insurers will give patients faster access to health care with "fewer challenges navigating the health system." ...

CVS Caremark stops coverage for Eli Lilly's weight loss drug Zepbound, citing high costs, while obesity specialists warn the decision disrupts patient treatment.

Eli Lilly’s Zepbound transformed weight loss drug market since debut 18 months ago 4.5 million people reportedly taking Lilly ...

Health insurance companies, including CVS Caremark, are altering coverage for GLP-1 weight loss medications like Zepbound, leaving millions to navigate significant cost changes. Prescription savings ...